	Breakthrough										
					WAC (as of date	Date of		therapy	Priority	Date and price of acquisition if the	A description of the marketing and
Manufacture	er				of commercial	Commercial	Estimated volume of patients	designation?	Review?	drug was not developed by the	pricing plans used in the launch of the
Name	NDC	Name of Prescription Drug	Strength	Pack Size/Volume	availability)	Availability	who may be prescribed drug	(Y/N)	(Y/N)	manufacturer else N/A	new drug
											This drug is a generic drug and marketed
											in traditional generic ways through
											typical wholesale and chargeback
AvKare, Inc.	. 42291-0205-16 Phei	nobarbital with Belladonna Alkaloids Elixir	16.2 MG/ML	480 ML	\$1,297.83	3/16/2021	N/A	N	N	N/A	channels.